Clinical Trial Update: Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study evaluating ganaxolone as a candidate for smoking cessation; study completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• ganaxolone (ganaxolone)

Snippet

Sponsor: Jed E. Rose | Conditions: Smoking Cessation | Phase 2 | Status: COMPLETED | Results posted: 2014-09-08